Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Phase 2 study of PTI-428 drug in people with CF ages 18 and older who have two copies of the F508del CFTR mutation (Proteostasis PTI-428-06) , protocol number NCT03591094 PTI-428-06

    This randomized, placebo-controlled study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of the drug PTI-428 and how it is processed by the body. It is for people with CF ages 18 and older who have two copies of the F508del CFTR mutation and are already taking tezacaftor/ivacaftor.

    • Age:

      18 years and older

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      10

    • Length of Participation:

      74 days

    Contact us about this clinical Trial >
  • Mucociliary ClearanceCompleted with results Location: USA

    Phase 3 study of inhaled mannitol in adults with cystic fibrosis , protocol number NCT02134353 DPM-CF-303

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the inhaled drug mannitol and will use a placebo control.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirements

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      5

    • Length of Participation:

      6

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: Multicentre

    A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis Harbouring One F508del CFTR Mutation and a Second Gating (Class III) Mutation , protocol number NCT03045523 GLPG2222-CL-201

    This clinical study is a phase IIa, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate two doses of orally administered GLPG2222 in adult subjects with a confirmed diagnosis of CF harbouring one F508del CFTR mutation and a second gating (class III) mutation and on stable treatment with ivacaftor. Up to 35 evaluable subjects are planned to be included in the study. Eligible subjects must be on stable treatment with physician prescribed ivacaftor (Kalydeco®) for at least 28 days at the baseline visit. They will be randomized in a 2:2:1 ratio to receive one of two active doses of GLPG2222 (150 mg q.d. or 300 mg q.d.) or placebo q.d. administered for 29 days. Subjects will be in the study for a minimum of 6 weeks and a maximum of 10 weeks, from screening until the follow-up visit.

    • Age:

      18 years and older

    • Mutation(s):

      One F508del mutation on one allele in the CFTR gene, a gating (class III) mutation (one of the following: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R) on the 2nd allele in the

    • FEV1% Predicted:

      (FEV1) ≥ 40% of predicted normal for age, gender and height at screening

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple US sites

    PREDICT: NTM observational study (NTM-OB-17) , protocol number NCT02073409 NTM-OB-17

    This study is taking place at multiple care centers across the U.S. It will evaluate the current standard of diagnosing nontuberculous mycobacteria (NTM) in people with CF.

    • Age:

      10 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      20

    • Length of Participation:

      5 Years

    Contact us about this clinical Trial >
  • Restore CFTR FunctionRecruiting Location: Multiple care centres across the US & VIC, Australia

    Phase 3 study of long-term ivacaftor in babies who have a CFTR gating mutation , protocol number NCT03277196 VX-770-126

    This open-label study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of long-term ivacaftor in babies who have a CFTR gating mutation.

    • Age:

      0 days to 24 months

    • Mutation(s):

      One copy F508del or no copies F508del

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      18

    • Length of Participation:

      128 weeks

    Contact us about this clinical Trial >
  • Anti-InflammatoryEnrolling Location: Multiple care centres across the US

    Phase 2 study of lenabasum in people with CF ages 12 and older (Corbus JBT101-CF-002) , protocol number NCT03451045 JBT101-CF-002

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug lenabasum and will use a placebo control.

    • Age:

      12 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40-100%

    • Number of Visits:

      10

    • Length of Participation:

      32 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US

    Phase 2a study of Galapagos GLPG2222 in adults with CF , protocol number NCT03119649 Galapagos GLPG2222-CL-202

    This study evaluated the safety and effectiveness of the CFTR modulator GLPG2222. This study was for people with CF who have two copies of the F508del mutation.

    • Age:

      18 years and older

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      5

    • Length of Participation:

      10 weeks

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple US sites

    Rare Mutation Cell Collection (RARE) , protocol number NCT 03161808 NCT 03161808

    This study is taking place at multiple care centres across the US. Researchers will collect and make available for study cells from people with rare CFTR mutations.

    • Age:

      2 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40-90%

    • Number of Visits:

      8

    • Length of Participation:

      30 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: USA, Australia, Europe

    Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor , protocol number NCT02549451 VX15-809-110

    Study 110 is a Phase 3, multicenter study in subjects aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation and who participated in Study 109 (NCT02514473) or Study 011B (NCT01897233). Study 110 is designed to evaluate the safety and efficacy of long term treatment of lumacaftor in combination with ivacaftor.

    • Age:

      6-11 years and 12 years and older

    • Mutation(s):

      Homozygous for the F508del-CFTR Mutation

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Mucociliary ClearanceEnrolling Location: Multiple care centres across the US

    Phase 1Bstudy of inhaled AZD5634 in adults with CF , protocol number NCT02950805

    This study is taking place at multiple care centres accross the US. It will look at the safety and tolerability of the inhaled drug AZD5634 in adults with CF.

    • Age:

      18 - 60 years

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      4

    • Length of Participation:

      4 months

    Contact us about this clinical Trial >
  • Displaying results 91-100 (of 178)
     |<  <  6 - 7 - 8 - 9 - 10 - 11 - 12 - 13 - 14 - 15  >  >|